We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01604733
First Posted: May 24, 2012
Last Update Posted: May 24, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
May 21, 2012
May 24, 2012
May 24, 2012
October 2010
June 2011   (Final data collection date for primary outcome measure)
The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , overall and by country [ Time Frame: 24 weeks ]
Same as current
No Changes Posted
  • The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes [ Time Frame: 24 weeks ]
  • The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Third Joint European Task Force guideline, in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes [ Time Frame: 24 weeks ]
  • Determinants (e.g. patient and physician characteristics , country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia [ Time Frame: 24 weeks ]
  • Physician characteristics associated with the allocation of treatment regimen. [ Time Frame: 24 weeks ]
  • The proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the sub-population patients with fasting triglycerides<200 mg/d [ Time Frame: 24 weeks ]
Same as current
Not Provided
Not Provided
 
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Observational
Time Perspective: Cross-Sectional
Not Provided
Retention:   None Retained
Description:
blood sample
Non-Probability Sample
Community patients
Hypercholesterolemia
Not Provided
HYPERCHOLESTEROLEMIC PATIENTS
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1000
June 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks
  • Subject must provide informed consent and comply with the survey procedures

Exclusion Criteria:

  • Less than 18 years less than 3 months on antidyslipidemic agent Subjects who are unwilling or unable to provide informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01604733
NIS-EG-CRE-2010/01
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Study Chair: Mohie E Sherif, MD Ethical committee, Faculty of medicine, Alexandria University
AstraZeneca
May 2012